Open access

Showing results 81 - 90 of 100

Sorted by most recent

TitleAuthorDate

EPO promotes the progression of rheumatoid arthritis by inducing desialylation via increasing the expression of neuraminidase 3

Gan Wu, Ben Cao, Haige Zhai, Bin Liu, Yuan Huang, Xiaowei Chen, Hanzhi Ling, Sunwang Ling, Shengwei Jin, Xinyu Yang, Jianguang Wang

25 January 2024

Male patients with inflammatory joint diseases are less likely than controls to be childless: results from a Norwegian population-based cohort study of 10 865 patients

Gudrun David Sigmo, Solveig Hauge, Karl Ove Hufthammer, Marianne Wallenius, Kjell Åsmund Salvesen, Anne Kjersti Nesje Daltveit, Gunnstein Bakland, Bjorg-Tilde Svanes Fevang

23 January 2024

CD7 activation regulates cytotoxicity-driven pathology in systemic sclerosis, yielding a target for selective cell depletion

Theodoros Ioannis Papadimitriou, Prashant Singh, Arjan van Caam, Birgitte Walgreen, Mark A J Gorris, Elly L Vitters, Iris L van Ingen, Marije I Koenders, Ruben L Smeets, Madelon Vonk, Jolanda M de Vries, Peter M van der Kraan, Ypke van Oosterhout, Martijn A Huynen, Hans J P M KoenenSee the full list of authors

18 December 2023

Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression

Sofia Pitsigavdaki, Myrto Nikoloudaki, Panagiotis Garantziotis, Ettore Silvagni, Argyro Repa, Antonio Marangoni, Irini Flouri, Nestor Avgoustidis, Konstantinos Parperis, Antonis Fanouriakis, Marcello Govoni, Prodromos Sidiropoulos, Dimitrios T Boumpas, Alessandra Bortoluzzi, George Bertsias

17 January 2024

Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial

Di Wu, Jing Li, Dong Xu, Joan T Merrill, Ronald F van Vollenhoven, Yi Liu, Jiankang Hu, Yang Li, Fen Li, Chenghui Huang, Guochun Wang, Xiaomei Li, Jianhong Zhao, Dongbao Zhao, Cibo HuangSee the full list of authors

21 December 2023

Third-generation CD19.CAR-T cell-containing combination therapy in Scl70+ systemic sclerosis

Wolfgang Merkt, Merle Freitag, Maren Claus, Philipp Kolb, Valeria Falcone, Manuel Röhrich, Lea Rodon, Franca Deicher, Ivana Andreeva, Theresa Tretter, Lars-Oliver Tykocinski, Norbert Blank, Carsten Watzl, Anita Schmitt, Tim SauerSee the full list of authors

22 December 2023

Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the ‘JAK-pot’ study)

Romain Aymon, Denis Mongin, Sytske Anne Bergstra, Denis Choquette, Catalin Codreanu, Diederik De Cock, Lene Dreyer, Ori Elkayam, Doreen Huschek, Kimme L Hyrich, Florenzo Iannone, Nevsun Inanc, Lianne Kearsley-Fleet, Suleyman Serdar KOCA, Tore K KvienSee the full list of authors

8 December 2023

CD19-targeting CAR T cells protect from ANCA-induced acute kidney injury

Dörte Lodka, Maria Zschummel, Mario Bunse, Anthony Rousselle, Janis Sonnemann, Ralph Kettritz, Uta E Höpken, Adrian Schreiber

5 January 2024

Randomised trial of genetic testing and targeted intervention to prevent the development and progression of Paget’s disease of bone

Jonathan Phillips, Deepak Subedi, Steff C Lewis, Catriona Keerie, Owen Cronin, Mary Porteous, David Moore, Roseanne Cetnarskyj, Lakshminarayan Ranganath, Peter L Selby, Tolga Turgut, Geeta Hampson, Rama Chandra, Shu Ho, Jon TobiasSee the full list of authors

20 December 2023

Single-cell resolution of longitudinal blood transcriptome profiles in rheumatoid arthritis, systemic lupus erythematosus and healthy control pregnancies

Hilde Julie T Lien, Tina T Pedersen, Bente Jakobsen, Arnar Flatberg, Konika Chawla, Pål Sætrom, Mona H Fenstad

30 November 2023

Prev 1 2 3 4 5 6 7 8910 Next